Cara Therapeutics IncNASDAQ:CARANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6000/ 1
- Ask / Lots0.7890/ 1
- Open / Previous Close0.0000 / 0.6900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARA |
|---|---|---|
| 09:32 ET | 1598 | 0.7104 |
| 09:34 ET | 11285 | 0.7103 |
| 09:36 ET | 7265 | 0.7103 |
| 09:41 ET | 845 | 0.71 |
| 09:43 ET | 1390 | 0.7 |
| 09:45 ET | 1100 | 0.6996 |
| 09:48 ET | 6283 | 0.6997 |
| 09:50 ET | 1655 | 0.699161 |
| 09:52 ET | 200 | 0.7088 |
| 09:54 ET | 694 | 0.717783 |
| 09:56 ET | 100 | 0.7128 |
| 09:59 ET | 100 | 0.7149 |
| 10:01 ET | 1666 | 0.7149 |
| 10:06 ET | 100 | 0.7149 |
| 10:12 ET | 100 | 0.7149 |
| 10:14 ET | 200 | 0.714827 |
| 10:15 ET | 240 | 0.71 |
| 10:19 ET | 660 | 0.7083 |
| 10:21 ET | 1141 | 0.705 |
| 10:26 ET | 100 | 0.7 |
| 10:30 ET | 100 | 0.7145 |
| 10:32 ET | 530 | 0.7145 |
| 10:33 ET | 680 | 0.7 |
| 10:35 ET | 721 | 0.6977 |
| 10:37 ET | 500 | 0.6977 |
| 10:46 ET | 100 | 0.6977 |
| 10:48 ET | 1355 | 0.7098 |
| 10:50 ET | 174 | 0.6978 |
| 10:51 ET | 100 | 0.6977 |
| 10:55 ET | 896 | 0.7 |
| 10:57 ET | 14759 | 0.71775 |
| 11:02 ET | 1465 | 0.71775 |
| 11:04 ET | 100 | 0.7214 |
| 11:06 ET | 219 | 0.71775 |
| 11:08 ET | 121 | 0.72139 |
| 11:11 ET | 200 | 0.7178 |
| 11:13 ET | 1880 | 0.72 |
| 11:15 ET | 527 | 0.7205 |
| 11:18 ET | 250 | 0.7205 |
| 11:20 ET | 385 | 0.7205 |
| 11:22 ET | 1250 | 0.7112 |
| 11:29 ET | 100 | 0.7205 |
| 11:31 ET | 100 | 0.71 |
| 11:36 ET | 100 | 0.7205 |
| 11:38 ET | 200 | 0.71 |
| 11:42 ET | 11539 | 0.7173 |
| 11:44 ET | 300 | 0.712143 |
| 11:45 ET | 200 | 0.71 |
| 11:47 ET | 1365 | 0.7173 |
| 11:49 ET | 1702 | 0.7152 |
| 11:51 ET | 300 | 0.7204 |
| 11:58 ET | 300 | 0.71 |
| 12:02 ET | 100 | 0.7199 |
| 12:03 ET | 100 | 0.71 |
| 12:05 ET | 283 | 0.7107 |
| 12:09 ET | 100 | 0.71 |
| 12:12 ET | 100 | 0.71 |
| 12:16 ET | 100 | 0.7113 |
| 12:18 ET | 200 | 0.71 |
| 12:20 ET | 998 | 0.7108 |
| 12:21 ET | 957 | 0.7116 |
| 12:25 ET | 1537 | 0.71 |
| 12:30 ET | 100 | 0.71 |
| 12:32 ET | 100 | 0.71 |
| 12:34 ET | 100 | 0.7116 |
| 12:36 ET | 12980 | 0.70575 |
| 12:38 ET | 400 | 0.7 |
| 12:43 ET | 100 | 0.7115 |
| 12:45 ET | 200 | 0.7003 |
| 12:48 ET | 100 | 0.7103 |
| 12:52 ET | 100 | 0.701 |
| 12:54 ET | 3600 | 0.7099 |
| 12:56 ET | 100 | 0.7013 |
| 12:59 ET | 2547 | 0.700836 |
| 01:01 ET | 478 | 0.7025 |
| 01:03 ET | 8857 | 0.6972 |
| 01:06 ET | 1330 | 0.6977 |
| 01:08 ET | 100 | 0.6929 |
| 01:10 ET | 1011 | 0.7042 |
| 01:14 ET | 100 | 0.6929 |
| 01:15 ET | 100 | 0.6929 |
| 01:19 ET | 807 | 0.6924 |
| 01:21 ET | 2039 | 0.693 |
| 01:24 ET | 252 | 0.6983 |
| 01:26 ET | 225 | 0.6901 |
| 01:28 ET | 1155 | 0.69 |
| 01:30 ET | 150 | 0.6831 |
| 01:32 ET | 114 | 0.683 |
| 01:33 ET | 11417 | 0.693 |
| 01:37 ET | 3335 | 0.69 |
| 01:42 ET | 100 | 0.684 |
| 01:44 ET | 200 | 0.6873 |
| 01:48 ET | 285 | 0.6936 |
| 01:50 ET | 671 | 0.683 |
| 01:53 ET | 400 | 0.6868 |
| 01:57 ET | 100 | 0.6899 |
| 02:02 ET | 100 | 0.6899 |
| 02:04 ET | 100 | 0.68 |
| 02:08 ET | 2500 | 0.6801 |
| 02:09 ET | 698 | 0.683 |
| 02:11 ET | 100 | 0.683 |
| 02:15 ET | 130 | 0.68 |
| 02:18 ET | 900 | 0.685 |
| 02:20 ET | 500 | 0.6899 |
| 02:22 ET | 100 | 0.6899 |
| 02:24 ET | 672 | 0.6899 |
| 02:26 ET | 7523 | 0.704 |
| 02:27 ET | 737 | 0.71 |
| 02:29 ET | 866 | 0.7099 |
| 02:31 ET | 3458 | 0.7092 |
| 02:33 ET | 3776 | 0.71 |
| 02:36 ET | 300 | 0.71 |
| 02:38 ET | 2711 | 0.712 |
| 02:40 ET | 658 | 0.715 |
| 02:42 ET | 2222 | 0.71705 |
| 02:45 ET | 200 | 0.7173 |
| 02:47 ET | 911 | 0.7173 |
| 02:49 ET | 1589 | 0.72 |
| 02:51 ET | 1079 | 0.7173 |
| 02:54 ET | 813 | 0.7181 |
| 02:56 ET | 700 | 0.7181 |
| 02:58 ET | 1134 | 0.7221 |
| 03:00 ET | 2606 | 0.7221 |
| 03:02 ET | 500 | 0.7251 |
| 03:03 ET | 700 | 0.7251 |
| 03:05 ET | 10782 | 0.73135 |
| 03:07 ET | 417 | 0.7361 |
| 03:09 ET | 3566 | 0.7317 |
| 03:12 ET | 400 | 0.72785 |
| 03:14 ET | 782 | 0.72785 |
| 03:16 ET | 2601 | 0.7273 |
| 03:18 ET | 1726 | 0.7273 |
| 03:20 ET | 2407 | 0.7164 |
| 03:21 ET | 813 | 0.716 |
| 03:23 ET | 4494 | 0.7014 |
| 03:25 ET | 3133 | 0.6975 |
| 03:27 ET | 4997 | 0.7027 |
| 03:30 ET | 513 | 0.7027 |
| 03:32 ET | 1590 | 0.7027 |
| 03:34 ET | 1698 | 0.6977 |
| 03:36 ET | 1433 | 0.69825 |
| 03:38 ET | 3132 | 0.69825 |
| 03:39 ET | 100 | 0.6977 |
| 03:41 ET | 1289 | 0.6988 |
| 03:43 ET | 2986 | 0.69775 |
| 03:45 ET | 8507 | 0.69535 |
| 03:48 ET | 422 | 0.695 |
| 03:50 ET | 4800 | 0.695 |
| 03:52 ET | 1500 | 0.695 |
| 03:54 ET | 400 | 0.6956 |
| 03:56 ET | 2500 | 0.6977 |
| 03:57 ET | 3862 | 0.695 |
| 03:59 ET | 8087 | 0.69 |
Apr 10, 2024
DJ Cara Therapeutics Price Target Maintained With a $5.00/Share by Needham, from 6:45AM ET on Wednesday Apr 10, 2024 by Dow Jones
6:45AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 2, 2024
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference, from 7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 28, 2024
DJ Cara Therapeutics Price Target Maintained With a $5.00/Share by Needham, from 5:50AM ET on Thursday Mar 28, 2024 by Dow Jones
5:50AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cara Therapeutics Inc | 37.7M | -0.3x | --- |
Prenetics Global Ltd | 38.9M | -0.7x | --- |
ImmuCell Corp | 39.1M | -6.8x | --- |
Aadi Bioscience Inc | 44.2M | -0.7x | --- |
Turnstone Biologics Corp | 62.6M | -1.0x | --- |
Viaderma Inc | 11.7M | 0.0x | --- |
Company Information
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Contact Information
- Headquarters
- 400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
- Phone
- 203-406-3700
- Fax
- 203-567-1510
Executives
- Independent Chairman of the Board
- Martin Vogelbaum
- President, Chief Executive Officer, Director
- Christopher Posner
- Chief Financial Officer
- Ryan Maynard
- Senior Vice President - Research and Development, Chief Scientific Officer
- Frederique Menzaghi
- Chief Compliance Officer, General Counsel, Secretary
- Scott Terrillion
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.7M |
|---|---|
Revenue (TTM) | $21.0M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.76 |
EPS | $-2.19 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -579.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
